

ERRATUM

## Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis

Philip Mease · Iain B. McInnes

Published online: July 25, 2016

© The Author(s) 2016. This article is published with open access at Springerlink.com

Erratum to: Rheumatol Ther (2016) 3:5–29  
DOI 10.1007/s40744-016-0031-5

In the original version, the second paragraph (last sentence) of the section “Efficacy of Secukinumab in Patient Subgroups” under heading FUTURE 1 AND FUTURE 2, a value is incorrect. The correct sentence should read as:

The Week 52 observed data were 62.1% for secukinumab 300 mg, 48.3% for secukinumab 150 mg, and 63.2% for secukinumab 75 mg (Fig. 12b).

### OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

---

The online version of the original article can be found under doi:[10.1007/s40744-016-0031-5](https://doi.org/10.1007/s40744-016-0031-5).

---

P. Mease (✉)  
Swedish Medical Center and the University of  
Washington, Seattle, WA, USA  
e-mail: [pmease@philipmease.com](mailto:pmease@philipmease.com)

I. B. McInnes  
Institute of Infection, Immunity and Inflammation,  
University of Glasgow, Glasgow, UK